首页> 外文期刊>Journal of aerosol medicine and pulmonary drug delivery >Mucociliary and cough clearance as a biomarker for therapeutic development.
【24h】

Mucociliary and cough clearance as a biomarker for therapeutic development.

机译:粘膜纤毛和止咳作为治疗发展的生物标志物。

获取原文
获取原文并翻译 | 示例
           

摘要

A workshop/symposium on "Mucociliary and Cough Clearance (MCC/CC) as a Biomarker for Therapeutic Development" was held on October 21-22, 2008, in Research Triangle Park, NC, to discuss the methods for measurement of MCC/CC and how they may be optimized for assessing new therapies designed to improve clearance of airway secretions from the lungs. The utility of MCC/CC as a biomarker for disease progression and therapeutic intervention is gaining increased recognition as a valuable tool in the clinical research community. A number of investigators currently active in using MCC/CC for diagnostic or therapeutic evaluation presented details of their methodologies. Attendees participating in the workshop discussions included those interested in the physiology of MCC/CC, some of who use in vitro or animal methods for its study, pharmaceutical companies developing muco-active therapies, and many who were interested in establishing the methods in their own clinical laboratory. This review article summarizes the presentations for the in vivo human MCC/CC methods and the discussions both at and subsequent to the workshop between the authors to move forward on a number of questions raised at the workshop.
机译:2008年10月21日至22日,在北卡罗来纳州三角研究园举行了关于“尿毒症和咳嗽清除剂(MCC / CC)作为治疗发展的生物标志物”的讲习班/研讨会,讨论了MCC / CC和如何优化它们以评估旨在改善从肺中清除气道分泌物的新疗法。 MCC / CC作为疾病进展和治疗干预的生物标志物的实用性正日益得到认可,已成为临床研究界的宝贵工具。当前活跃于使用MCC / CC进行诊断或治疗评估的许多研究人员详细介绍了他们的方法。参加研讨会讨论的与会者包括对MCC / CC的生理学感兴趣的人员,一些使用体外或动物方法进行研究的人员,开发粘液活性疗法的制药公司以及许多对自己建立方法感兴趣的人员临床实验室。这篇综述文章总结了体内人MCC / CC方法的介绍,以及研讨会之间以及作者之间的讨论,以推进研讨会上提出的许多问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号